Cell and Gene Therapy, Industry, News
February 12, 2021
Via: Pharma TimesBeti-cel, marketed as Zynteglo in Europe, is a gene therapy intended for the treatment of transfusion-dependent beta-thalassaemia (TDT) in people aged 12 years and older who do not have a beta0/beta0 genotype. It is indicated for TDT patients when haematopoietic […]
July 19, 2024
July 11, 2024
July 11, 2024